EU Lists Spinal Cord Inflammation Probable Side Effect Of JNJ's COVID-19 Shot: Reuters

European Medicines Agency (EMA) recommended adding transverse myelitis, a rare type of spinal inflammation, as a side-effect of the Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine.
Giving updates on the safety of all coronavirus shots, the EMA said it was assessing reports of capillary leak syndrome, a rare blood condition after Moderna Inc's (NASDAQ:MRNA) vaccine.
The EMA said it had recorded six cases of capillary leak syndrome and was assessing all data, but it was not yet clear if there was a causal association between the reports and the vaccine.
The EMA said there was insufficient evidence of a possible link between rare cases of the multisystem inflammatory syndrome and mRNA-based vaccines from Moderna and Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX) vaccine.
Price Action: JNJ shares traded lower by 0.83 at $162.90 on the last check Thursday.